

GENOX



1. Product Name

GENOX, 10 mg and 20 mg, tablets.

2. Qualitative and Quantitative Composition

Each tablet contains 10 mg or 20 mg of tamoxifen (as citrate).

For the full list of excipients, see section 6.1.

3. Pharmaceutical Form

Each GENOX 10 tablet contains 10 mg of tamoxifen (as tamoxifen citrate). GENOX 10 is presented as white, biconvex, tablets, marked "TN" over "10" on one side and G on the reverse.

Each GENOX 20 tablet contains 20 mg of tamoxifen (as tamoxifen citrate). GENOX 20 is presented as white, biconvex tablets, marked "TN" above a score and "20" below the score on one side and G on the reverse.

4. Clinical Particulars

4.1 *Therapeutic indications*

GENOX is indicated for the treatment of breast cancer.

4.2 *Dose and method of administration*

Adults

The initial dose is 20 mg once daily. In advanced breast cancer, if no response is seen, dosage may be increased to 40 mg once daily.

Children

GENOX is not indicated for use in children.

4.3 *Contraindications*

GENOX must not be given during pregnancy. Premenopausal patients must be carefully examined before treatment for breast cancer to exclude the possibility of pregnancy.

GENOX should not be given to patients who have experienced hypersensitivity to the product or any of its excipients listed in section 6.1.

4.4 *Special warnings and precautions for use*

An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours) has been reported in association with tamoxifen treatment. The incidence and pattern of this increase suggest that the underlying

mechanism is related to the oestrogenic properties of tamoxifen. Any patients receiving or having previously received tamoxifen, who report abnormal gynaecological symptoms, especially vaginal bleeding, should be promptly investigated.

In a large randomized trial in Sweden of adjuvant tamoxifen 40 mg/day for 2-5 years, an increased incidence of uterine cancer was noted. Twenty three of 1,372 patients randomized to receive tamoxifen versus 4 of 1,357 patients randomized to the observation group developed cancer of the uterus [RR=5.6; (1.9-16.2), p<0.001].

One of the patients with cancer of the uterus who was randomized to receive tamoxifen never took the drug. After approximately 6.8 years of follow-up in the ongoing NSABP B-14¹ trial, 15 of 1,419 women randomized to receive tamoxifen 20 mg/day for 5 years developed uterine cancer and 2 of the 1,424 women randomized to receive placebo, who subsequently had recurrent breast cancer and were treated with tamoxifen, also developed uterine cancer. Most of the uterine cancers were diagnosed at an early stage, but deaths from uterine cancer have been reported.

Patients receiving tamoxifen should have routine gynaecological care and report any abnormal vaginal bleeding to their physician.

In an uncontrolled trial in 28 girls aged 2-10 with McCune Albright Syndrome (MAS), who received 20 mg once a day for up to 12 months duration, mean uterine volume increased after 6 months of treatment and doubled at the end of the one-year study. While this finding is in line with the pharmacodynamic properties of tamoxifen, a causal relationship has not been established. Tamoxifen is not approved for treatment of McCune Albright Syndrome.

There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy. When tamoxifen is co-administered with chemotherapy, there may be a further increase in the incidence of thromboembolic effects. For treatment of breast cancer, the risks and benefits of tamoxifen should be carefully considered in women with a history of thromboembolic events.

In delayed microsurgical breast reconstruction tamoxifen may increase the risk of microvascular flap complications.

A number of second primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.

Cases of visual disturbances, including infrequent reports of corneal changes, and common reports of retinopathy have been described in patients receiving tamoxifen therapy. Cataracts have commonly been reported in association with the administration of tamoxifen.

Tamoxifen should be used cautiously in patients with existing leucopenia or thrombocytopenia. Leucopenia has been observed following the administration of tamoxifen sometimes in association with anaemia and/or thrombocytopenia. Neutropenia has been reported on rare occasions; this can sometimes be severe and rarely cases of agranulocytosis have been reported. Decreases in platelet counts, usually to 50,000 to 100,000/mm³, infrequently lower, have been occasionally reported in patients taking tamoxifen for breast cancer. Periodic complete blood counts, including platelet counts, may be appropriate.

Poor metabolisers of CYP2D6 may have a reduced response to tamoxifen due to reduced plasma concentrations of the active metabolite, endoxifen. Concomitant medicines that inhibit CYP2D6 may reduce the concentration of the active tamoxifen metabolite, endoxifen. Some studies have shown reduced efficacy of tamoxifen as measured by the risk of breast cancer recurrence and mortality, when taken with CYP2D6 inhibitors. Common CYP2D6 inhibitors include paroxetine, fluoxetine and bupropion. Women taking tamoxifen should avoid using CYP2D6 inhibitors wherever possible (see section 4.5).

¹ The NSABP (National Surgical Adjuvant Breast and Bowel Project) B-14 trial is undergoing reaudit and information from this study may be subject to change.

Use in premenopausal women

It should be noted that only a small number of premenopausal women have been treated, since candidates for therapy are usually postmenopausal, either reaching a natural menopause, or having menopause induced by surgery or radiotherapy. Menstruation is suppressed in a proportion of premenopausal women receiving tamoxifen for the treatment of breast tumours. Ovarian cysts have occasionally been observed in women receiving tamoxifen.

Paediatric use

GENOX is not indicated for use in children (see section 4.2).

Effects on laboratory tests

No data available.

4.5 Interaction with other medicines and other forms of interaction

When tamoxifen is used in combination with coumarin type anticoagulants, a significant increase in anticoagulant effect may occur. Where such co-administration is initiated, careful monitoring of the patient is recommended.

When tamoxifen is used in combination with cytotoxic agents, there is increased risk of thromboembolic events occurring..

The use of tamoxifen in combination with an aromatase inhibitor as adjuvant therapy has not shown improved efficacy compared with tamoxifen alone.

The known principal pathway for tamoxifen metabolism in humans is demethylation, catalysed by CYP3A4 enzymes. Pharmacokinetic interaction with the CYP3A4 inducing agent rifampicin, showing a reduction in tamoxifen plasma levels has been reported in the literature.

Cytochrome P450 2D6 (CYP2D6) plays an important role in the metabolism of tamoxifen. CYP2D6 helps convert tamoxifen to endoxifen (a potent active metabolite of tamoxifen). Therefore, co-administration of tamoxifen with CYP2D6 inhibitors such as paroxetine, fluoxetine and bupropion may reduce plasma levels of endoxifen and should be avoided where possible (see section 4.4).

4.6 Fertility, pregnancy and lactation

Effects on fertility

No data available.

Use in pregnancy (Category B3)

Tamoxifen must not be administered during pregnancy. There have been a small number of reports of spontaneous abortions, birth defects and foetal deaths after women have taken tamoxifen, although no causal relationship has been established (see section 4.3).

Reproductive toxicology studies in rats, rabbits and monkeys have shown no teratogenic potential.

In rodent models of foetal reproductive tract development, tamoxifen was associated with changes similar to those caused by oestradiol, ethinyloestradiol, clomiphene and diethylstilboestrol (DES). Although the clinical relevance of these changes is unknown, some of them, especially vaginal adenosis, are similar to those seen in young women who were exposed to DES *in utero* and who have a 1 in 1000 risk of developing clear-cell carcinoma of the vagina or cervix. Only a small number of pregnant women have been exposed to tamoxifen. Such exposure has not been reported to cause subsequent vaginal adenosis or clear-cell carcinoma of the vagina or cervix in young women exposed *in utero* to tamoxifen.

Women should be advised not to become pregnant whilst taking tamoxifen and for nine months following the cessation of therapy and should use barrier or other non-hormonal contraceptive methods if sexually active.

Premenopausal patients must be carefully examined before treatment to exclude pregnancy. Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking tamoxifen or within nine months of cessation of therapy.

Use in lactation

It is not known if tamoxifen is excreted in human milk and therefore the drug is not recommended during lactation.

4.7 Effects on ability to drive and use machines

Fatigue has been reported with the use of tamoxifen. Therefore, caution should be observed when driving or operating machinery while such symptoms persist.

4.8 Undesirable effects

The adverse reactions which have been reported are of two types: those associated specifically with the pharmacological action of the drug e.g. hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae, tumour pain and tumour flare and those of a more general nature, e.g. gastrointestinal intolerance, headache, light-headedness and, occasionally, fluid retention and alopecia. In patients treated with tamoxifen for metastatic breast cancer, the most frequent adverse reactions are hot flushes, nausea and vomiting. These may occur in up to one-fourth of patients. Less frequently reported adverse reactions are vaginal bleeding, vaginal discharge, menstrual irregularities, alopecia and increased bone and tumour pain. Other adverse reactions which are seen infrequently are hypercalcaemia, peripheral oedema, pruritus vulvae, dizziness and light-headedness. Infrequent cases of endometrial, ocular and haematological adverse effects have been reported (see section 4.4). When such adverse reactions are severe, it may be possible to control them by a simple reduction of dosage (within the recommended dose range) without loss of control of the disease. If adverse reactions do not respond to this measure, it may be necessary to stop the treatment.

Skin rashes (including isolated reports of erythema multiforme, Stevens-Johnson syndrome, cutaneous vasculitis, and bullous pemphigoid) and commonly hypersensitivity reactions, including angioedema have been reported.

Although hypercalcaemia may occur in patients with advanced breast cancer, uncommonly patients with bony metastases have developed hypercalcaemia on initiation of therapy with tamoxifen.

Uterine fibroids, endometriosis and other endometrial changes including hyperplasia and polyps have been reported.

Cystic ovarian swellings have occasionally been observed in premenopausal women receiving tamoxifen. Vaginal polyps have rarely been observed in women receiving tamoxifen.

There is evidence of ischaemic cerebrovascular events and thromboembolic events, including deep vein thrombosis, microvascular thrombosis and pulmonary embolism, occurring commonly during tamoxifen therapy. When tamoxifen is used in combination with cytotoxic agents, there is increased risk of thromboembolic events occurring.

Uncommonly, cases of interstitial pneumonitis have been reported.

Leg cramps and myalgia have been reported commonly in patients receiving tamoxifen.

Tamoxifen has been associated with changes in liver enzyme levels and with a spectrum of more severe liver abnormalities which in some cases were fatal, including fatty liver, cholestasis and hepatitis, liver failure, cirrhosis and hepatocellular injury (including hepatic necrosis).

Commonly, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of tamoxifen.

An increased incidence of endometrial cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours) has been reported in association with tamoxifen treatment.

Cutaneous lupus erythematosus has been observed very-rarely in patients receiving tamoxifen.

Porphyria cutanea tarda has been observed very-rarely in patients receiving tamoxifen.

Cases of optic neuropathy and optic neuritis have been rarely reported in patients receiving tamoxifen and in a small number of cases blindness has occurred.

Sensory disturbances (including paraesthesia and dysgeusia) have been reported commonly in patients receiving tamoxifen.

Fatigue has been reported very commonly in patients taking tamoxifen.

Radiation recall has been observed very rarely in patients receiving tamoxifen.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions <https://nzphvc.otago.ac.nz/reporting/>.

4.9 Overdose

On theoretical grounds, an overdosage would be expected to cause enhancement of the pharmacological side effects mentioned above. Observations in animals show that extreme overdosage (100 to 200 times the equivalent of the recommended daily human dose) may produce oestrogenic effects.

There have been reports in the literature that tamoxifen given at several times the standard dose may be associated with prolongation of the QT interval of the ECG.

There is no specific antidote to overdosage, and treatment must be symptomatic.

For further advice on management of overdose please contact the National Poisons Information Centre (0800 POISON or 0800 764 766).

5. Pharmacological Properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Anti-estrogens, ATC code: L02BA01

GENOX (tamoxifen) is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor.

5.2 Pharmacokinetic properties

Tamoxifen is metabolised mainly via CYP3A4 to N-desmethyltamoxifen, which is further metabolised by CYP2D6 to another active metabolite endoxifen. In patients who lack the enzyme CYP2D6, endoxifen concentrations are approximately 75% lower than in patients with normal CYP2D6 activity. Administration of strong CYP2D6 inhibitors reduces endoxifen circulating levels to a similar extent

Absorption

Tamoxifen is absorbed from the gastrointestinal tract. However, the site and extent of absorption is not known. Peak serum levels of 15 to 25 nanogram/mL were observed three to six hours after administration of a single oral dose of 10 mg tamoxifen. Steady state serum levels are achieved after approximately 4 weeks therapy. Mean steady state values after dosing at 20 mg twice daily were 285 ± 19 nanogram/mL and 477 ± 35 nanogram/mL for tamoxifen and N-desmethyltamoxifen respectively.

Bioavailability

No information available.

Distribution

Little information is available in humans. It has been found in the uterus and ovary, particularly in the endometrium and corpus luteum. Radioactivity studies in animals show high levels in the liver, lung, ovary and spleen. Low levels have been found in the pituitary, eyes and brain.

Protein binding

The drug appears to be bound to an unknown degree to cytoplasmic protein receptors in all oestrogen target tissues, and is highly protein bound to serum albumin (>99%).

Metabolism

Tamoxifen undergoes extensive metabolism in the liver by hydroxylation, demethylation and conjugation, giving rise to several metabolites. The major circulating metabolite of tamoxifen in humans is N-desmethyltamoxifen which has a pharmacological profile very similar to that of tamoxifen and thus contributes to the therapeutic effect. Other minor metabolites are formed, some of which also have antioestrogenic activity.

Excretion

The elimination of tamoxifen and its major metabolite N-desmethyltamoxifen is slow. This leads to extensive accumulation of both compounds in serum during chronic administration. Tamoxifen is mainly excreted via the faeces, with only small amounts appearing in the urine. The drug is excreted mainly as its conjugates. In one patient studied for 13 days after dosing, approximately 50% of the dose had been excreted in the faeces, and 13% in the urine. In animals, tamoxifen undergoes enterohepatic circulation, and is thought to do so in humans.

In a clinical study where girls between 2 and 10 years with McCune Albright Syndrome (MAS) received 20 mg tamoxifen once a day for up to 12 months duration, there was an age-dependent decrease in clearance and an increase in exposure (AUC), (with values up to 50% higher in the youngest patients) compared with adults.

Half-life

The elimination half-life of tamoxifen is estimated to be 5 to 7 days and 10 to 14 days for N-desmethyltamoxifen.

Clinical implications of pharmacokinetic data

As the main site of metabolism is the liver, and accumulation of the drug and its active metabolites is possible with prolonged treatment, dose and dosing interval may need adjustment in patients with liver disease.

5.3 Preclinical safety data

Genotoxicity

Tamoxifen was genotoxic in some *in vitro* tests and *in vivo* genotoxicity tests in rodents. Gonadal tumours in mice and liver tumours in rats receiving tamoxifen have been reported in long-term studies. The clinical relevance of these findings has not been established.

Carcinogenicity

Tamoxifen was not mutagenic in a range of *in vitro* and *in vivo* mutagenicity tests.

6. Pharmaceutical Particulars

6.1 List of excipients

GENOX Tablets also contain:

- mannitol
- maize starch
- croscarmellose sodium and
- magnesium stearate.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

5 years.

6.4 Special precautions for storage

Store at or below 25°C, protect from light.

6.5 Nature and contents of container

PP bottle with PP cap. Pack-size of 30 tablets (10 mg) or 20 tablets (20 mg).

Al/PVC blister pack. Pack-size of 30, 60, or 100 tablets.

Not all pack types and sizes may be marketed.

6.6 Special precautions for disposal

Not applicable.

7. Medicines Schedule

Prescription Medicine

8. Sponsor Details

Mylan New Zealand Ltd
PO Box 11183
Ellerslie
AUCKLAND
Customer Services Freephone: 0800 579 811

9. Date of First Approval

18 July 1985

10. Date of Revision of the Text

04 May 2021

Summary table of changes

Section	Summary of new information
4.4	Information on thromboembolic events added. Minor edits
4.6	Information on pregnancy updated. Fertility sub-heading added.

5.2	Formatting.
5.3	Information updated on carcinogenicity.
6.1	Formatting updates Removal of claim of being gluten and lactose free.
8	Sponsor phone number updated